283 studies found for:    Exclude Unknown | Expanded Access Studies
Show Display Options
Rank Status Study
21 Available Expanded Access Treatment Protocol CA204-143
Condition: Multiple Myeloma
Intervention: Drug: Elotuzumab
22 Available 68Ga-DOTATOC for Imaging of Neuroendocrine Tumors: Expanded Access Trial
Condition: Neuroendocrine Tumors
Intervention: Drug: 68Ga-DOTATOC PET/CT Scan
23 Temporarily not available An Open Protocol for the Compassionate Use of Trametinib
Condition: Cancer
Intervention: Drug: Trametinib
24 Available OMS721 Compassionate Use in Patients With Thrombotic Microangiopathy
Condition: Thrombotic Microangiopathy
Intervention: Biological: OMS721
25 Temporarily not available Detecting Recurrent Prostate Cancer With C-11 Choline Positron Emission Tomography: An Expanded Access Study
Condition: Cancer of the Prostate
Intervention: Drug: C-11 Choline PET Imaging
26 No longer available TX2® Low Profile Endovascular Graft
Conditions: Aortic Aneurysm;   Penetrating Ulcer;   Vascular Disease
Intervention: Device: TX2® Low Profile TAA Endovascular Graft
27 Available A Dose Escalation Study of Intravenous L-citrulline in Steady-state Sickle Cell Disease
Condition: Sickle Cell Disease
Intervention: Drug: Intravenous (IV) citrulline
28 Temporarily not available FMT for Multidrug Resistant Organism Reversal
Condition: Infection With Multi-drug Resistant Organisms
Intervention: Biological: Fecal microbiota transplantation (FMT)
29 Available Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Condition: CD33 Positive Acute Myelogenous Leukemia
Intervention: Biological: Antibody Drug Conjugate Chemotherapeutic
30 Available Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France
Conditions: Gastric Cancer;   Gastroesophageal Junction Adenocarcinoma
Interventions: Drug: Ramucirumab;   Drug: Paclitaxel
31 Temporarily not available Extended Access Program for Subjects Completing Perampanel Study E2007-G000-332
Condition: Seizure Disorder Generalized Tonic Clonic
Intervention: Drug: Perampanel
32 No longer available Emergency Administration of EPI-743 to a Single Patient With Leber's Hereditary Optic Neuropathy [LHON]
Condition: Leber's Hereditary Optic Neuropathy
Intervention: Drug: EPI-743
33 No longer available A Single Patient IND for PD-0325901
Condition: Prior Treatment With PD-0325901 With Ongoing Clinical Response
Intervention: Drug: PD-0325901
34 Available Expanded Access Study of Talimogene Laherparepvec for Treatment of Subjects With Unresected Stage IIIB-IVM1c Melanoma
Condition: Unresected Stage IIIB to IVM1c Melanoma
Intervention: Drug: Talimogene Laherparepvec
35 Available Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer
Condition: Colorectal Cancer Metastatic
Intervention: Drug: TAS-102
36 Available Expanded Access Protocol Thymus Transplantation
Conditions: Poor Thymic Function;   Immunodeficiency;   Athymia;   Immunoreconstitution;   Thymus Transplantation;   Low T Cell Numbers
Interventions: Biological: Thymus Transplantation;   Procedure: Blood Draw;   Drug: Rabbit Anti-Thymocyte Globulin and Cyclosporine or Tacrolimus
37 Available Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic Transplantation
Conditions: Chronic Myeloid Leukemia;   Myelodysplastic Syndrome;   Acute Myeloid Leukemia
Intervention: Biological: G-CSF mobilized CD34+ selected cells for transplantation
38 Available Humanitarian Use of AVANTA Orthopaedics Proximal Interphalangeal Joint
Condition: Arthroplasty of the PIP Joint
Intervention: Device: SR™ PIP
39 Approved for marketing Use of Avanta Metacarpophalangeal (MCP) Joint Implant Finger Prosthesis, Humanitarian Use Device
Condition: Arthroplasty of the MCP Joint
Intervention: Device: SR™MCP
40 Available Expanded Access Use of Stiripentol in Dravet Syndrome or Sodium Channel Mutation Epileptic Encephalopathies
Conditions: Dravet Syndrome;   Epileptic Encephalopathies Associated With SCN1A Mutations
Intervention: Drug: Stiripentol

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years